Novartis Invests $3 Billion in PTC's PTC518 Huntington's Program with Milestone Payments and Global Licensing Rights

The Novartis and PTC partnership marks a significant collaboration in the field of Huntington's disease treatment, centering around the development of PTC518, an innovative drug candidate designed to lower mutant huntingtin protein production. Under the terms of the agreement, Novartis will make an upfront payment of $1 billion for global rights, with potential additional milestone payments totaling up to $1.9 billion, depending on developmental, regulatory, and sales milestones[1][2]. PTC will maintain a 40% profit share in the U.S. and benefit from double-digit tiered royalties on international sales. This strategic alliance leverages PTC's expertise in splicing therapies with Novartis's global development resources in neuroscience[3]. Completion of the PIVOT-HD study for PTC518 is anticipated by early 2025, after which Novartis will assume responsibility for the drug's further development[1].